cis-alpha-trans-Bergamotol is a sandalwood-associated sesquiterpene alcohol that appears repeatedly in AromaForge sandalwood records. The evidence base located in this pass is strongest for identity, occurrence, and biosynthesis rather than isolated pharmacology: public sources support the compound as a named sandalwood sesquiterpenol and as a product of the Santalum album CYP76F oxidation pathway. For archive purposes it should be framed as a sandalwood composition marker with sparse constituent-specific human or toxicology data.
Aroma and practical use
- Use the recorded woody, soft, sandalwood-like, smooth descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2013 PLOS One paper functionally characterized Santalum album CYP76F cytochromes P450 and reported bergamotol among the oxidation products generated in the sandalwood oil pathway.
A 2013 PLOS One paper functionally characterized Santalum album CYP76F cytochromes P450 and reported bergamotol among the oxidation products generated in the sandalwood oil pathway.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A supplier COA for New Caledonia sandalwood listed cis-alpha-trans-Bergamotol at 8.05% with an additional smaller bergamotol peak later in the chromatogram, showing that this isomer label is not only theoretical but used in live analytical records.
A supplier COA for New Caledonia sandalwood listed cis-alpha-trans-Bergamotol at 8.05% with an additional smaller bergamotol peak later in the chromatogram, showing that this isomer label is not only theoretical but used in live analytical records.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2024 review on sandalwood oil biology described bergamotol among the major sandalwood sesquiterpenoids and focused on composition and biosynthesis more than isolated pharmacology.
A 2024 review on sandalwood oil biology described bergamotol among the major sandalwood sesquiterpenoids and focused on composition and biosynthesis more than isolated pharmacology.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot assessed
Not assessed in the available record.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot assessed
Not assessed in the available record.
Penetration enhancementNot assessed
Not assessed in the available record.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No strong constituent-specific toxicology or dermal-limit monograph for cis-alpha-trans-Bergamotol was verified in this pass; most accessible safety discussion applies to sandalwood oil as a whole.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Because bergamotol naming varies across analytical datasets, safety interpretation should not assume every bergamotol-labeled peak refers to an identical stereochemical assignment.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
cyp76f_oxidation_of_bergamotene_precursors
Santalum album CYP76F enzymes oxidize bergamotene-derived precursors to bergamotol within the core sandalwood oil biosynthetic pathway.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- The live search found little isolated pharmacology for cis-alpha-trans-Bergamotol apart from sandalwood mixture context and biosynthesis work.
- Isomer naming is inconsistent across databases and GC reports, which limits confidence in cross-source stereochemical equivalence.
- Standalone dermal, inhalation, and systemic safety references for this single constituent were limited.
- A c6 verification search (2026-07-13) found no RIFM/IFRA safety assessment or dermal-limit citation for cis-alpha-trans-bergamotol (CAS 88034-74-6); the prior unsourced 20% dermal_limit_pct and sensitizing:true were corrected to null.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.